Clare Bradley1, Eveline Eschwège2, Pedro de Pablos-Velasco3, Klaus G Parhofer4, Dominique Simon5,6, Hans Vandenberghe7, Linda Gönder-Frederick8. 1. Health Psychology Research Unit, Royal Holloway, University of London, Egham, U.K. c.bradley@rhul.ac.uk. 2. INSERM, Paris, France. 3. Dr. Negrin Hospital, Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain. 4. Medical Department 4, Grosshadern, Klinikum der Universität München, Munich, Germany. 5. Institute of Cardiometabolism and Nutrition, Hôpital de la Pitié-Salpêtrière, Paris, France. 6. Diabetes Department, Hôpital de la Pitié-Salpêtrière, Paris, France. 7. AstraZeneca, Uccle, Belgium. 8. University of Virginia Health System, Charlottesville, VA.
Abstract
OBJECTIVE: PANORAMA, a nine-country cross-sectional type 2 diabetes study, investigated factors associated with quality of life (QoL), health status, and other patient-reported outcome measures (PROMs). RESEARCH DESIGN AND METHODS: Patients were randomly or consecutively selected from primary/secondary care. PROMs included the Audit of Diabetes-Dependent Quality of Life (ADDQoL) (generic QoL item and average weighted impact [AWI] scores), Diabetes Treatment Satisfaction Questionnaire (DTSQ) (patient- and physician-completed), Hypoglycemia Fear Survey-II worry subscale, and the EuroQoL-5 Dimension visual analog scale (EQ-VAS) measuring patient-reported health. Multivariable linear regression analyses determined predictors of each PROM including patient characteristics, physician-reported adherence, complications, and glycosylated hemoglobin. RESULTS: In 5,813 patients, mean PROM scores indicated that generic QoL approximated "good" (0.93); perceived impact of diabetes on QoL was negative (AWI -1.69). Treatment satisfaction exceeded physicians' estimates (patient-reported: 29.76; physician-estimated: 27.75), but so did patients' perceived frequency of hypo-/hyperglycemia. Worry about hypoglycemia (13.27) was apparent. Intensifying treatments to three oral agents or insulin regimens predicted worse QoL (AWI P < 0.01). Insulin alone use predicted worse QoL (generic P < 0.02; AWI P < 0.001) and hypoglycemia worry (P < 0.007). No treatment had significant associations with EQ-VAS health status. CONCLUSIONS: Predictors for different PROMs differed markedly and provided insights for understanding and improving these important outcomes. Intensive treatment regimens had significant negative associations with all PROMs, except the EQ-VAS health status measure. The findings demonstrate the importance of measuring QoL alongside health status and other patient-reported outcomes when evaluating diabetes treatments with a view to protecting QoL and facilitating adherence and long-term glycemic control.
OBJECTIVE: PANORAMA, a nine-country cross-sectional type 2 diabetes study, investigated factors associated with quality of life (QoL), health status, and other patient-reported outcome measures (PROMs). RESEARCH DESIGN AND METHODS: Patients were randomly or consecutively selected from primary/secondary care. PROMs included the Audit of Diabetes-Dependent Quality of Life (ADDQoL) (generic QoL item and average weighted impact [AWI] scores), Diabetes Treatment Satisfaction Questionnaire (DTSQ) (patient- and physician-completed), Hypoglycemia Fear Survey-II worry subscale, and the EuroQoL-5 Dimension visual analog scale (EQ-VAS) measuring patient-reported health. Multivariable linear regression analyses determined predictors of each PROM including patient characteristics, physician-reported adherence, complications, and glycosylated hemoglobin. RESULTS: In 5,813 patients, mean PROM scores indicated that generic QoL approximated "good" (0.93); perceived impact of diabetes on QoL was negative (AWI -1.69). Treatment satisfaction exceeded physicians' estimates (patient-reported: 29.76; physician-estimated: 27.75), but so did patients' perceived frequency of hypo-/hyperglycemia. Worry about hypoglycemia (13.27) was apparent. Intensifying treatments to three oral agents or insulin regimens predicted worse QoL (AWI P < 0.01). Insulin alone use predicted worse QoL (generic P < 0.02; AWI P < 0.001) and hypoglycemia worry (P < 0.007). No treatment had significant associations with EQ-VAS health status. CONCLUSIONS: Predictors for different PROMs differed markedly and provided insights for understanding and improving these important outcomes. Intensive treatment regimens had significant negative associations with all PROMs, except the EQ-VAS health status measure. The findings demonstrate the importance of measuring QoL alongside health status and other patient-reported outcomes when evaluating diabetes treatments with a view to protecting QoL and facilitating adherence and long-term glycemic control.
Authors: Moshe Phillip; Richard M Bergenstal; Kelly L Close; Thomas Danne; Satish K Garg; Lutz Heinemann; Irl B Hirsch; Boris P Kovatchev; Lori M Laffel; Viswanathan Mohan; Christopher G Parkin; Tadej Battelino Journal: Diabetes Technol Ther Date: 2020-09-28 Impact factor: 6.118
Authors: Richard M Bergenstal; Mark Peyrot; Darlene M Dreon; Vanita R Aroda; Timothy S Bailey; Ronald L Brazg; Juan P Frias; Mary L Johnson; David C Klonoff; Davida F Kruger; Shenaz Ramtoola; Julio Rosenstock; Pierre Serusclat; Ruth S Weinstock; Ramachandra G Naik; David M Shearer; Vivien Zraick; Brian L Levy Journal: Diabetes Technol Ther Date: 2019-04-26 Impact factor: 6.118
Authors: Elena-Daniela Grigorescu; Cristina-Mihaela Lăcătușu; Ioana Crețu; Mariana Floria; Alina Onofriescu; Alexandr Ceasovschih; Bogdan-Mircea Mihai; Laurențiu Șorodoc Journal: Int J Environ Res Public Health Date: 2021-03-21 Impact factor: 3.390